Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. We show 31 historical shares outstanding datapoints in our CTXR shares outstanding history coverage, used to compute CTXR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTXR market cap history over the course of time is important for investors
interested in comparing CTXR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTXR versus a peer is one thing; comparing
CTXR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTXR can fluctuate over the course of history.
With this page we aim to empower investors researching CTXR by allowing them to research the CTXR market cap history. |
Free CTXR Email Alerts:
Video: The Importance of Market Cap
